• Myeloma UK
  • Clinical Service Excellence Programme
Myeloma Academy
Sign inRegister
Menu
  • Home
  • CPD & Learning
    • Myeloma Nurse Learning Programme
    • My CPD Portfolio
    • Challenging Cases
    • Close
  • Library
    • Guidelines
      • Complications
      • COVID-19 guidance
      • General haemato/oncology
      • Imaging & Analysis
      • Management & Treatment
      • Palliative Care
      • Presentation & Diagnosis
      • Related conditions
      • Close
    • Patient Support and Information
    • Medical animations
    • Close
  • Resources
    • Myeloma Drug Finder
    • Myeloma Trial Finder
    • Assessment tools
    • Myeloma Spotlight
    • Primary care education
    • Secondary care education
    • Myeloma health economic model
    • Close
  • News & Events
    • News
    • Event calendar
    • Meeting highlights
    • Close
  • CSEP
  • About Us
    • Contact Us
    • Close
Menu back  
 

Supportive care

A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
Iyer SP et al. Br J Haematol. 2014 Aug 19. doi: 10.1111/bjh.13056. [Epub ahead of print].

Effect of Clodronate Treatment on Risk of Fracture: A Systematic Review and Meta-analysis.
Frediani B et al. Calcif Tissue Int. 2014 Aug 12. [Epub ahead of print].

A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR).
Pasquali S et al. J Nephrol. 2014 Aug 23. [Epub ahead of print].

Miconazole mucoadhesive buccal tablet in high-dose therapy with autologous stem cell transplantation (HDT/ASCT)-induced mucositis.
Orvain C et al. Support Care Cancer. 2014 Aug 3. [Epub ahead of print]

  • Guidelines
  • Patient Support and Information
  • Medical animations
Bottom menu

Charity No. SC 026116
Myeloma UK
22 Logie Mill
Beaverbank Business Park
Edinburgh
EH7 4HG